The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. received a Schedule 13G reporting that a group of Viking-related entities and three named individuals may be deemed to beneficially own 2,666,690 shares of the company’s common stock, representing 5.5% of the outstanding class based on 48,384,150 shares outstanding following a private placement. The filing breaks ownership down: Viking Global Opportunities (VGOP) directly owns 1,600,014 shares (3.3%) and Viking Global Opportunities Drawdown (VGOD) directly owns 1,066,676 shares (2.2%). All reporting persons report only shared voting and dispositive power and no sole voting or dispositive power. The filing lists Oruka’s principal executive office in Menlo Park, CA, and provides the reporting persons’ business address in Stamford, CT. Signatures are dated 09/24/2025.
Oruka Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement of common stock and pre-funded warrants, raising an aggregate purchase price of approximately $180 million from institutional and accredited investors. Investors bought 10,933,405 shares of common stock at $15.00 per share and pre-funded warrants to purchase 1,066,666 shares at $14.999 per warrant, with a $0.001 per share exercise price.
The pre-funded warrants are exercisable at any time, subject to beneficial ownership limits initially set at 9.99%, adjustable up to 19.99% with 61 days’ notice. Following closing, Oruka reports 48,384,150 shares of common stock issued and outstanding and approximately 67.1 million shares issued and outstanding on a pro forma basis as of September 19, 2025, reflecting full conversion of Series B preferred stock and exercise of all pre-funded warrants.
Fairmount Funds Management LLC and affiliated entities report beneficial ownership of 11,162,741 shares of Oruka Therapeutics, Inc. common stock, representing 19.99% of the outstanding shares based on 55,841,629 shares as of September 17, 2025. This total includes 3,705,262 directly held shares, pre-funded warrants for 1,253,572 shares and conversion rights for 6,203,907 shares of Series B preferred stock, each subject to stated beneficial ownership limitations. On September 17, 2025 Fund II purchased 333,340 shares in a PIPE at $15.00 per share for $5,000,100; the PIPE closed on September 19, 2025. The investors received registration rights requiring the company to file an initial resale registration statement by October 15, 2025. Certain additional shares issuable upon exercise or conversion are excluded from the reported totals because they would exceed the contractual ownership caps.
Oruka Therapeutics insiders and affiliated funds reported a private placement purchase of common stock on 09/17/2025. The filing shows 333,340 shares were acquired at $15.00 per share in a transaction described as a private placement exempt under Rule 16b-3(d)(1). The report lists beneficial ownership following the transaction of 1,131,954 shares attributed to Fairmount Healthcare Fund II L.P. and 2,573,308 shares attributed to Fairmount Healthcare Co-Invest III L.P., each held indirectly. Fairmount Funds Management LLC is the manager of those funds and identifies Peter Harwin and Tomas Kiselak as its managers; they disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated 09/19/2025.
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies for psoriasis and inflammatory diseases. As of June 30, 2025 the company reported $65.4 million in cash, $286.1 million in marketable securities (totaling $351.5 million), total assets of $357.4 million and stockholders' equity of $343.6 million. For the three and six months ended June 30, 2025 the company recorded net losses of $24.6 million and $45.6 million, respectively, and used $44.0 million of cash in operating activities during the first half of 2025. Research and development was the primary expense, totaling $44.0 million for six months.
The company advanced its pipeline: ORKA-001 (anti-IL-23p19) completed Phase 1 dosing in healthy volunteers, received FDA IND and Health Canada CTA clearances and commenced Phase 2a dosing with the first patient dosed subsequent to the quarter end; ORKA-002 (anti-IL-17A/F) initiated Phase 1 dosing. Oruka holds exclusive licenses with Paragon that include milestone payments (up to $12.0 million clinical and $10.0 million regulatory per program) and low single-digit royalties; it has expensed $4.0 million for each license. Management expects existing cash, cash equivalents and marketable securities to fund operating plans for at least twelve months from issuance of these financial statements.
On July 1, 2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 4 reporting that Chief Operating Officer Laura Lee Sandler received an employee stock option covering 25,000 shares of common stock at an exercise price of $11.80 per share. The option expires on June 30, 2035 and vests 25 % on July 1, 2026, with the remaining 75 % vesting in equal monthly installments thereafter (1⁄48 per month). After the grant, Sandler beneficially owns 25,000 derivative securities; no non-derivative share transactions were disclosed. The filing reflects an incentive-based award rather than an open-market purchase or sale, resulting in no immediate cash flow or share-count impact for investors.
On 07/01/2025, Oruka Therapeutics, Inc. (ORKA) filed a Form 3 reporting the initial beneficial ownership of its newly appointed Chief Operating Officer, Laura Lee Sandler.
- Direct ownership: 213,084 shares of common stock.
- Derivative securities: • Warrant covering 99,996 shares at an exercise price of $7.80, expiring 07/14/2034. Vesting schedule: 25% on 04/03/2025, remaining shares vest monthly over the subsequent three years. • Employee stock option for 137,500 shares at $12.50, expiring 01/21/2035; vests 1/48 monthly beginning 01/01/2025.
- Potential total ownership: 450,580 shares if all derivatives vest and are exercised.
The disclosure signals meaningful insider alignment through equity ownership and a performance-linked vesting structure. No other transactions or financial metrics were included in this filing.